Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats

Behavioural Brain Research

Volumn 294, Issue , 2015, Pages 177-185

  Burgdorf, Jeffrey ^a   Kroes, Roger A ^b   Zhang, Xiao lei ^c   Gross, Amanda L ^b   Schmidt, Mary ^b   Weiss, Craig ^d   Disterhoft, John F ^d   Burch, Ronald M ^b   Stanton, Patric K ^c   Moskal, Joseph R ^a,b  

^a Northwestern University   (United States)

^b Naurex Inc   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Depression; GLYX 13; LTP; Medial Prefrontal Cortex; NMDA Receptor

Indexed keywords

MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; RAPASTINEL; SUCROSE; TRANSCRIPTOME; AMINO ACID RECEPTOR AFFECTING AGENT; GLYX-13 PEPTIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOPEPTIDE; PSYCHOTROPIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; CARBOHYDRATE METABOLISM; CELL METABOLISM; CHRONIC UNPREDICTABLE STRESS; COMPARATIVE STUDY; CONNECTOME; CONTEXTUAL FEAR CONDITIONING; CONTEXTUAL FEAR EXTINCTION; CONTROLLED STUDY; DEPRESSION; ELECTROPHYSIOLOGY; EMOTIONAL LEARNING; FEAR; FEAR RECONSOLIDATION; FORCED SWIM TEST; GLUTAMATERGIC SYNAPSE; HYPOPHAGIA; INTERRATER RELIABILITY; LEARNING; LIPID METABOLISM; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MALE; MEDIAL PREFRONTAL CORTEX; METAPLASTICITY PROCESS; NERVE CELL PLASTICITY; NONHUMAN; NOVELTY INDUCED HYPOPHAGIA TESTING; PHYSICAL PARAMETERS; PORSOLT FORCED SWIM TEST; POSITIVE EMOTIONAL LEARNING; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; RAT; SIGNAL TRANSDUCTION; SUCROSE PREFERENCE TESTING; SYNAPSE; THERAPY EFFECT; TRANSCRIPTOMICS; TREATMENT DURATION; UPREGULATION; ANIMAL; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; MEMORY; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; SPRAGUE DAWLEY RAT; STRESS DISORDERS, POST-TRAUMATIC; TISSUE CULTURE TECHNIQUE; UNCERTAINTY;

ANIMALS; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGENTS; LEARNING; LONG-TERM POTENTIATION; MALE; MEMORY; OLIGOPEPTIDES; PREFRONTAL CORTEX; PSYCHOTROPIC DRUGS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PSYCHOLOGICAL; TISSUE CULTURE TECHNIQUES; TRANSCRIPTOME; UNCERTAINTY;

EID: 84939600416     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.07.039     Document Type: Article

References (41)

1. Moskal J.R., Kuo A.G., Weiss C., Wood P.L., O'Connor Hanson A., Kelso S., et al. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator. Neuropharmacology 2005, 49:1077-1087.
2. Zhang X.L., Sullivan J.A., Moskal J.R., Stanton P.K. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008, 55:1238-1250.
3. Burgdorf J., Zhang X.L., Weiss C., Matthews E., Disterhoft J.F., Stanton P.K., et al. The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol. Aging 2011, 32:698-706.
4. Burgdorf J., Zhang X.-I., Nicholson K.L., Balster R.L., Leander J.D., Stanton P.K., et al. GLYX-13, an NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without ketamine-Like Side Effects. Neuropsychopharmacology 2013, 38:729-742.
5. Breslau N., Kessler R.C., Chilcoat H.D., Schultz L.R., Davis G.C., Andreski P. Trauma and posttraumatic stress disorder in the community: the 1996 detroit area survey of trauma. Arch. Gen. Psychiatry 1998, 55:626-632.
6. Parsons R.G., Ressler K.J. Implications of memory modulation for post-traumatic stress and fear disorders. Nat. Neurosci. 2013, 16:146-153.
7. Maren S., Phan K.L., Liberzon I. The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat. Rev. Neurosci. 2013, 14:417-428.
8. Yamamoto S., Morinobu S., Fuchikami M., Kurata A., Kozuru T., Yamawaki S. Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD. Neuropsychopharmacology 2008, 33:2108-2116.
9. Milad M.R., Rauch S.L., Pitman R.K., Quirk G.J. Fear extinction in rats: implications for human brain imaging and anxiety disorders. Biol. Psychol. 2006, 73:61-71.
10. Knight D.C., Cheng D.T., Smith C.N., Stein E.A., Helmstetter F.J. Neural substrates mediating human delay and trace fear conditioning. J. Neurosci. Off. J. Soc. Neurosci. 2004, 24:218-228.
11. de Kleine R.A., Hendriks G.J., Kusters W.J., Broekman T.G., van Minnen A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol. Psychiatry 2012, 71:962-968.
12. Rothbaum B.O., Price M., Jovanovic T., Norrholm S.D., Gerardi M., Dunlop B., et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am. J. Psychiatry 2014, 171:640-648.
13. Difede J., Cukor J., Wyka K., Olden M., Hoffman H., Lee F.S., et al. d-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 2014, 39:1052-1058.
14. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol. 2007, 18:391-418.
15. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
16. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry. 2011, 69:754-761.
17. Sanchez C., Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?. Psychopharmacology 1997, 129:197-205.
18. Burgdorf J., Kroes R.A., Weiss C., Oh M.M., Disterhoft J.F., Brudzynski S.M., et al. Positive emotional learning is regulated in the medial prefrontal cortex by GluN2B-containing NMDA receptors. Neuroscience 2011, 192:515-523.
19. Akirav I., Segev A., Motanis H., Maroun M. d-cycloserine into the BLA reverses the impairing effects of exposure to stress on the extinction of contextual fear, but not conditioned taste aversion. Learn. Mem. 2009, 12.
20. Parent M.A., Wang L., Su J., Netoff T., Yuan L.L. Identification of the hippocampal input to medial prefrontal cortex in vitro. Cereb. Cortex 2010, 20:393-403.
21. Kroes R.A., Panksepp J., Burgdorf J., Otto N.J., Moskal J.R. Modeling depression: social dominance-submission gene expression patterns in rat neocortex. Neuroscience 2006, 137:37-49.
22. Burgdorf J., Kroes R.A., Beinfeld M.C., Panksepp J., Moskal J.R. Uncovering the molecular basis of positive affect using rough-and-tumble play in rats: a role for insulin-li ke growth factor I. Neuroscience 2010, 168:769-777.
23. Corcoran M.E., Kroes R.A., Burgdorf J.S., Moskal J.R. Regional changes in gene expression after limbic kindling. Cell. Mol. Neurobiol. 2011.
24. Crosson L.A., Kroes R.A., Moskal J.R., Linsenmeier R.A. Gene expression patterns in hypoxic and post-hypoxic adult rat retina with special reference to the NMDA receptor and its interactome. Mol. Vis. 2009, 15:296-311.
25. Harris M.A., Clark J., Ireland A., Lomax J., Ashburner M., Foulger R., et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004, 32:D258-D261.
26. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
27. Huang da W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
28. Feder A., Parides M.K., Murrough J.W., Perez A.M., Morgan J.E., Saxena S., et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014, 71:681-688.
29. Heresco-Levy U., Gelfin G., Bloch B., Levin R., Edelman S., Javitt D.C., et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 2012, 501-506.
30. Heresco-Levy U., Javitt D.C., Gelfin Y., Gorelik E., Bar M., Blanaru M., et al. Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J. Affect. Disord. 2006, 93:239-243.
31. Iadarola N.D., Niciu M.J., Richards E.M., Vande Voort J.L., Ballard E.D., Lundin N.B., et al. Ketamine and other N-methyl-d-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther. Adv. Chron. Dis. 2015, 6:97-114.
32. Morgan C.J., Curran H.V. Independent Scientific Committee on D. Ketamine use: a review. Addiction 2011, 107:27-38.
33. Moskal J.R., Burch R., Burgdorf J.S., Kroes R.A., Stanton P.K., Disterhoft J.F., et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin. Investig. Drugs 2014, 23:243-254.
34. Richter-Levin G., Maroun M. Stress and amygdala suppression of metaplasticity in the medial prefrontal cortex. Cereb. Cortex 2010, 20:2433-2441.
35. Schmidt M.V., Abraham W.C., Maroun M., Stork O., Richter-Levin G. Stress-induced metaplasticity: from synapses to behavior. Neuroscience 2013, 250:112-120.
36. Maroun M., Richter-Levin G. Exposure to acute stress blocks the induction of long-term potentiation of the amygdala-prefrontal cortex pathway in vivo. J. Neurosci.: Off. J. Soc. Neurosci. 2003, 23:4406-4409.
37. Emmett M.R., Kroes R.A., Moskal J.R., Conrad C.A., Priebe W., Laezza F., et al. Integrative biological analysis for neuropsychopharmacology. Neuropsychopharmacology 2014, 39:5-23.
38. Moskal J.R., Burgdorf J., Kroes R.A., Brudzynski S.M., Panksepp J. A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism. Neurosci. Biobehav. Rev. 2011, 35:1982-1988.
39. Corcoran M.E., Kroes R.A., Burgdorf J.S., Moskal J.R. Regional changes in gene expression after limbic kindling. Cell. Mol. Neurobiol. 2011, 31:819-834.
40. Kroes R.A., Burgdorf J., Otto N.J., Panksepp J., Moskal J.R. Social defeat, a paradigm of depression in rats that elicits 22-kHz vocalizations, preferentially activates the cholinergic signaling pathway in the periaqueductal gray. Behav. Brain Res. 2007, 182:290-300.
41. Moskal J.R., Kroes R.A., Otto N.J., Rahimi O., Claiborne B.J. Distinct patterns of gene expression in the left and right hippocampal formation of developing rats. Hippocampus 2006, 16:629-634.